Enabling E-Biotech
Executive Summary
Approached creatively, the Web offers biotechs a distribution medium for the selling of expertise as expertise, rather than as therapeutic products, and its application to many problems, not a specific few. Such a strategy is directly contradictory to a biotech model built around exclusive collaborations. But the Web-enabled possibility of selling expertise broadly changes the biotech's customer base. Where biotechs currently look to sell a few, high-cost deals in which most of the funding comes at the end of a highly risky project, the Web-biotech sells to many subscribers who pay up front.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.